Erasca (ERAS) Is Up 10.4% After $225M Follow-On Offering And RAS Pipeline Updates - Has The Bull Case Changed? [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
This fundraising, coupled with encouraging updates on its RAS-focused programs like ERAS-0015 and ERAS-4001, has sharpened investor attention on Erasca's drug development prospects and balance sheet strength. We'll now examine how this sizeable capital raise and progress in RAS-targeted therapies could shape Erasca's broader investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Erasca today, you really need to believe that its RAS-focused pipeline can eventually turn promising early data into approved drugs, despite zero revenue and ongoing losses. The January 2026 follow-on offering at US$10.00 per share meaningfully strengthens the balance sheet, which could extend the cash runway and reduce near term funding concerns, but it also adds dilution on top of a share price that has already moved very sharply over the past year. That new capital and
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Mizuho Initiates Erasca (ERAS) With ‘Outperform' Rating and $16 PT [Yahoo! Finance]Yahoo! Finance
- Erasca (NASDAQ:ERAS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $16.00 price target on the stock.MarketBeat
- Erasca (NASDAQ:ERAS) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Erasca (NASDAQ:ERAS) had its price target raised by analysts at HC Wainwright from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Erasca (NASDAQ:ERAS) was given a new $10.00 price target on by analysts at Morgan Stanley.MarketBeat
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 1/30/26 - Form 4
- 1/30/26 - Form 4
- 1/30/26 - Form 4
- ERAS's page on the SEC website